Majority in India's big states with Covid-19 antibodies, finds survey

As of Wednesday, a total of 440 million Indian adults had received at least one COVID-19 shot, with just over 10% of its eligible population fully vaccinated.

Chhatrapati Shivaji Maharaj Terminus Railway Station
Reuters
2 min read Last Updated : Jul 28 2021 | 6:26 PM IST
More than 70% of people in eight of India's large states are estimated to have COVID-19 antibodies, a government survey showed on Wednesday, suggesting that a second surge in infections affected many more people than the reported figures.

The survey, which tested a sample of the population for the presence of COVID-19 antibodies, was conducted in June and July and showed that two-thirds of India's 1.3 billion people were likely to have been exposed to the virus. read more

The sero-prevalance survey, which tested around 29,000 people across the country, showed that in eight of India's largest and most populous states, more than 70% had antibodies for COVID-19, according to a government statement.

In the central state of Madhya Pradesh, 79% of its estimated population of 70.3 million had antibodies, the survey showed.

At least 75% of the population in the impoverished and densely populated eastern state of Bihar showed the presence of antibodies, as did 71% of the 220 million people in the country's most populous state of Uttar Pradesh, data showed.

India's daily cases have fallen after a devastating second wave that overwhelmed the healthcare system. On Wednesday, it reported 43,654 new cases and 640 deaths, down from a peak of 414,188 daily cases reported on May 7.

India's vaccination has picked up after a lull in April and May, but it may still not be able to meet its stated aim of inoculating all 950 million adults by the end of the year. read more

As of Wednesday, a total of 440 million Indian adults had received at least one COVID-19 shot, with just over 10% of its eligible population fully vaccinated.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story